When Innovation Outpaces Standardization – Solutions to Support Novel Wound Care Product Development

Novel products are critical within the global medical device marketplace. These state-of-the-art devices—and industry investment in them—deliver life-enhancing therapies, diagnostics and digital solutions to patients that need them most.

Hand-in-hand with product modernization, innovative test methods support efficacy and safety claims of novel products as standard test methods may not be fit for purpose. The use of appropriate test methods can support rapid product development and regulatory approval. Conversely, incorrect test methods can slow product development and hinder, or prolong, regulatory approval.

Join NAMSA as we discuss the components of customized test methods, the trend for regulatory bodies to demand even more clinically relevant In Vitro data and a review of case studies with real-world applications.

Attendees of this webinar can expect to walk away with a better understanding of the following:

• Wound care product categories: customized preclinical testing solutions to support innovation
• When to consider customized approaches
• Case Studies: proven solutions to demonstrate novel product efficacy or safety

Note: As of November 2024, NAMSA is no longer supporting testing related to the EN 13726 standard. If you have any questions on this change or would like to discuss further, please contact us.